Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

Oncoimmunology. 2014 Jun 25:3:e29244. doi: 10.4161/onci.29244. eCollection 2014.


Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4 and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and further uncovers how the expansion of the T cell repertoire matches the immunotoxicity profile of the therapy.

Keywords: CTLA-4; MK-3475; PBMC; PD-1; TCR; Tremelimumab; sequencing.